Comparative Pharmacology
Head-to-head clinical analysis: CARTEOLOL HYDROCHLORIDE versus KERLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTEOLOL HYDROCHLORIDE versus KERLONE.
CARTEOLOL HYDROCHLORIDE vs KERLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) with intrinsic sympathomimetic activity (ISA) and weak local anesthetic (membrane-stabilizing) activity. Reduces intraocular pressure by decreasing aqueous humor production.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Ophthalmic: Instill 1 drop of 1% or 2% solution into affected eye(s) twice daily. Oral: 2.5 mg to 5 mg once daily; may increase to 10 mg once daily if needed. Maximum dose 10 mg daily.
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may extend to 24-36 hours in severe renal impairment.
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug and active metabolite (8-hydroxycarteolol) accounts for 50-70% of elimination. Biliary/fecal excretion is minimal (<10%).
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Beta-Blocker
Beta-Blocker